Clinical trial
Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
NCT00008073 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00008073 |
|---|---|
| Title | Octreotide and Doxorubicin in Treating Patients With Advanced Cancer |
| Official title | Phase I Study Of Octreotide Acetate (Sandostatin) (SMS) As A Biomodulator Of Doxorubicin (DOX) |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | doxorubicin hydrochloride, octreotide acetate |
| Start date | Jan 1, 1996 |
| Primary completion | May 1, 2002 |
| Completion | May 1, 2002 |
| First posted | May 24, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: